Study to Assess Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED)
A Phase 3, Randomized, Double-mask, Placebo-controlled Study With Open-label Extension to Evaluate the Efficacy and Safety of Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED)
Sling Therapeutics, Inc.
130 participants
Aug 4, 2026
INTERVENTIONAL
Conditions
Summary
The goal of this clinical trial is to evaluate the efficacy, safety, and tolerability of linsitinib in participants with moderate to severe Thyroid Eye Disease (TED).
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
150 mg linsitinib is taken twice daily by mouth for 24 weeks
0 mg placebo taken twice daily by mouth for 24 weeks
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07753603